Co-Diagnostics Inc. (CODX)
Co-Diagnostics Inc. (CODX) Stock Price, Analysis & Data
No data available
| Bid | n/a |
| Market Cap | 7.88M |
| Revenue (ttm) | 721.39K |
| Net Income (ttm) | -47.06M |
| Beta | n/a |
| EPS (ttm) | -25.89 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.52 |
| P/B (ttm) | 0.48 |
| P/S (ttm) | 10.92 |
| Earnings Date | Nov 16, 2026 |
| Ask | n/a |
| Volume | 368,540 |
| Avg. Volume (20D) | 5,583,834 |
| Open | 1.30 |
| Previous Close | 1.34 |
| Day's Range | 1.26 - 1.32 |
| 52-Week Range | 1.26 - 46.50 |
| Analyst | Buy |
| Price Target | 4 (217.46%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CODX
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tub...
Financial Performance
In 2025, Co-Diagnostics's revenue was 622.49K, a decrease of -84.1% compared to the previous year's 3.92M. Earnings were -46.9M, an increase of 24.59%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for CODX stock is "Buy". The 12-month stock price forecast is 4, which is upside of 217.46% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
